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Abstract
Background Rosiglitazone and pioglitazone are high-affinity
peroxisome proliferator-activated receptor (PPAR)-γ agonists
with potent anti-diabetic properties and potential anti-
inflammatory effects. We compared the ability of a range of oral
doses of these thiazolidinediones, including those sufficient to
restore insulin sensitization, to inhibit the pathogenesis of
adjuvant-induced arthritis (AIA).
Methods AIA was induced in Lewis rats by a subcutaneous
injection of 1 mg of complete Freund's adjuvant. Rats were
treated orally for 21 days with pioglitazone 3, 10 or 30 mg/kg/
day, rosiglitazone 3 or 10 mg/kg/day, or with vehicle only. The
time course of AIA was evaluated by biotelemetry to monitor
body temperature and locomotor activity, by clinical score and
plethysmographic measurement of hindpaw oedema. At
necropsy, RT-PCR analysis was performed on synovium, liver
and subcutaneous fat. Changes in cartilage were evaluated by
histological examination of ankle joints, radiolabelled sulphate
incorporation (proteoglycan synthesis), glycosaminoglycan
content (proteoglycan turnover) and aggrecan expression in
patellar cartilage. Whole-body bone mineral content was
measured by dual-energy X-ray absorptiometry.
Results The highest doses of rosiglitazone (10 mg/kg/day) or
pioglitazone (30 mg/kg/day) were required to reduce fever
peaks associated with acute or chronic inflammation,
respectively, and to decrease arthritis severity. At these doses,
thiazolidinediones reduced synovitis and synovial expression of
TNF-α, IL-1β and basic fibroblast growth factor without affecting
neovascularization or the expression of vascular endothelial
growth factor. Thiazolidinediones failed to prevent cartilage
lesions and arthritis-induced inhibition of proteoglycan
synthesis, aggrecan mRNA level or glycosaminoglycan content
in patellar cartilage, but reduced bone erosions and
inflammatory bone loss. A trend towards lower urinary levels of
deoxipyridinolin was also noted in arthritic rats treated with
thiazolidinediones. Rosiglitazone 10 mg/kg/day or pioglitazone
30 mg/kg/day increased the expression of PPAR-γ and
adiponectin in adipose tissue, confirming that they were
activating PPAR-γ in inflammatory conditions, although an
increase in fat mass percentage was observed for the most anti-
arthritic dose.
Conclusion These data emphasize that higher dosages of
thiazolidinediones are required for the treatment of arthritis than
for restoring insulin sensitivity but that thiazolidinediones prevent
inflammatory bone loss despite exposing animals to increased
fatness possibly resulting from excessive activation of PPAR-γ.Page 1 of 16
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ACO = Acyl-CoenzymeA oxidase; AIA = adjuvant-induced arthritis; ANOVA = analysis of variance; bFGF = basic fibroblast growth factor; BMC = 
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= tumour necrosis factor; TZD = thiazolidinedione; VEGF = vascular endothelial growth factor.
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Adjuvant-induced arthritis (AIA) in the rat is an experimental
model reproducing some immunological aspects of rheuma-
toid arthritis (RA) such as genetic linkage and T-cell depend-
ence [1], as well as several pathological features including
chronic inflammation, involvement of peripheral joints, polysyn-
ovitis and secondary destruction of cartilage and bone [2]. Its
relevance to the pathogenesis of RA is further supported by
the demonstration that pro-inflammatory cytokines are highly
expressed in the developing arthritic process [3] and that clin-
ically relevant anti-cytokine therapy decreased arthritis severity
when used alone [4,5] or in combination [6,7]. In addition, the
AIA model reproduces most of the bone changes found in RA
[1], including inflammatory bone loss, which has been linked to
an increased risk of fracture [8]. Finally, the administration of
osteoprotegerin, a decoy receptor, prevented cortical and
trabecular bone loss in arthritic rats [9], suggesting that induc-
tion of osteoclast differentiation by receptor activator of
nuclear factor κB ligand (RANKL) in inflammatory synovium
could have a role [10]. This model is therefore suitable for the
study of the anti-arthritic and bone protective effects of drugs
thought to regulate cytokine expression at the gene level, such
as peroxisome proliferator-activated receptor (PPAR)-γ
agonists.
PPARs are ligand-inducible nuclear trans-acting factors
belonging to the steroid receptors family [11]. Among the
three characterized isotypes, PPAR-α is expressed essentially
in tissues contributing actively to the catabolism of fatty acids
(mainly in liver, and less markedly in brown fat, kidney, heart
and skeletal muscle), where it regulates the expression of
genes involved in fatty acid uptake and ω-oxidation or β-oxida-
tion [12]. PPAR-α is also expressed in endothelial and vascu-
lar smooth muscle cells, as well as in macrophages and foam
cells, where it contributes to the control of inflammation
[13,14]. PPAR-β/δ is expressed ubiquitously and takes part in
the reverse transport of cholesterol and the oxidation of fatty
acids [15]. It has profound anti-obesity and anti-diabetic
actions in animal models [16] and has also been linked to
wound healing [17]. PPAR-γ is highly expressed in adipose tis-
sue, where it has a pivotal role in adipocyte differentiation and
lipid storage [12]. Its activation has been linked to insulin-sen-
sitizing properties that have entered the clinics [14,18] and to
the suppression of the release of cytokines, resulting in anti-
inflammatory effects [19].
The anti-arthritic potency of PPAR agonists has been demon-
strated only rarely in patients with RA [20]. In contrast, several
studies have demonstrated the ability of PPAR agonists to
decrease the severity of experimental polyarthritis [21] with a
major effect on the expression of inflammatory genes [22-24]
or on oxidative stress [22,24]. However, some data were
obtained with 15-deoxy-Δ12,14-prostaglandin J2 [24,25], which
is known to have anti-inflammatory properties independently of
PPAR-γ activation [26]. Moreover, synthetic agonists were
sometimes administered in a non-classical way such as the
oral use of 10% dimethylsulphoxide as a vehicle [24] or
repeated intraperitoneal administration [25], which could pos-
sibly interfere with the arthritic process [27]. Finally, daily
doses of thiazolidinediones (TZDs) as high as 100 mg/kg/day
were reported to be effective in experimental arthritis [21,25]
although these doses are far above those required to restore
insulin sensitivity. As glitazones are used primarily as antidia-
betic agents, we decided to study the effects of rosiglitazone
and pioglitazone on the arthritic process, cartilage changes
and secondary bone loss when given orally at doses including
those shown previously to be effective as insulin sensitizers
[28-31].
In the present study we show that rosiglitazone 10 mg/kg/day
or pioglitazone 30 mg/kg/day were required to decrease
inflammation-induced fever and arthritis severity. At these anti-
inflammatory doses, TZDs decreased synovitis and the
expression of several cytokines and growth factors (TNF-α, IL-
1 and basic fibroblast growth factor (bFGF)) without affecting
neovascularization. However, none of the TZDs decreased
proteoglycan changes in arthritic cartilage while preventing
bone erosions and inflammatory bone loss. Both molecules
induced PPAR-γ-dependent responses in adipose tissue but
the maximal anti-arthritic effect was accompanied by
increased fatness in animals. These data demonstrate that the
anti-inflammatory potency of TZDs is of poor relevance to their
insulin-sensitizing properties and suggest that a strong activa-
tion of PPAR-γ may expose arthritic patients to drawbacks
secondary to excessive adipocyte differentiation.
Materials and methods
Animals
Ninety-three inbred male Lewis rats (Charles River, L'Arbresle,
France) weighing 150 to 175 g were acclimated for 1 week in
the laboratory before use. Animals were housed in groups of
three or four in solid-bottomed plastic cages with free access
to tap water and standard rodent pelleted chow (Scientific
Animal Food & Engineering A04, Villemoisson-sur-orge,
France) ad libitum. Room temperature was set at 23 ± 1°C
and animals were subjected to a 12-hour light cycle (with light
on from 06:00 to 18:00). All experiments were performed in
accordance with national animal care guidelines and were pre-
approved by a local ethics committee. Arthritis induction,
implantation of biotelemetry sensors, blood sampling and
necropsy were therefore performed under general anaesthe-
sia, using volatile anaesthetics (AErrane™; Baxter SA, Maure-
pas, France).
Induction of arthritis and treatment regimen
Arthritis was induced on day 0 at the basis of the tail by a sin-
gle subcutaneous injection of 0.1 ml of a suspension contain-
ing 10 mg/ml heat-inactivated Mycobacterium tuberculosis
H37Ra (Difco Laboratory, Detroit, MI, USA) emulsified in aPage 2 of 16
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mals served as controls (normal controls).
Animals were randomly assigned to one of the following treat-
ment groups: arthritic untreated controls (AIA controls),
arthritic rats treated with rosiglitazone (3 or 10 mg/kg/day) and
arthritic rats treated with pioglitazone (3, 10 or 30 mg/kg/day).
Treatment was given from the day of sensitization until
necropsy (day 21). Thiazolidinediones were administered
once a day by gastric gavage as a suspension in 0.5% car-
boxymethylcellulose at a dose of 1 ml per 100 g body weight.
Treatment was prepared daily from marketed pills of Avandia™
(Glaxo-Smith-Kline, Marly-le-Roy, France) and Actos™
(Takeda, Puteaux, France). Naive rats (normal controls) and
AIA controls received carboxymethylcellulose only.
Assessment of arthritis
Body weight
Total body weight was recorded every other day from day 6 to
day 21. At the indicated times, the increase in body weight
was calculated relative to that at day 0 allowing monitoring of
the decrease in body weight gain associated with arthritis.
Arthritic score
Animals were scored regularly until day 21 by two investiga-
tors who were blind to the treatment. Each paw was graded
according to the severity and extent of erythema and swelling
of periarticular soft tissues, and the enlargement and distortion
of the joints [32]. Clinical score ranged from 0 (no sign) to 4
(severe lesions), yielding a maximum score of 16 per animal.
Hindpaw oedema
Swelling of both hindpaws was measured regularly until day
21 by plethysmography. In brief, hindpaw volume was meas-
ured up to the skin–coat junction of the rear footpad through
the displacement of an equivalent volume of water in a plethys-
mometer 7150 (Apelex, Massy, France). At the indicated
times, paw volume was compared with the basal level (day 0)
and oedema was expressed as volume change (ml).
Evaluation of arthritis time course by biotelemetry
Body temperature and locomotive activity were monitored
hourly between 18:00 and 06:00 (dark cycle of nocturnal
intense activity) and recorded from day -1 (nocturnal data con-
trol) to day 17 with battery-operated biotelemetry devices
(Mini-Metter, model VMHF; Paris, France) implanted into the
peritoneal cavity [33]. In brief, the implanted sensor generates
radio frequency waves that are modulated by the waves radi-
ating from the animal (depending on body temperature) and
are detected by a receiver placed beneath the animal's cage.
Mobility is measured as pulses corresponding to signal
strengths generated by changes in the orientation of the
implanted transmitter relative to the T antenna of the receiver.
Signals are relayed by a consolidation matrix into a peripheral
processor connected to a computer. Fever was expressed as
the daily difference in the mean nocturnal temperature relative
to the mean nocturnal temperature recorded before sensitiza-
tion (day -1). The activity index was expressed as the daily per-
centage of the mean nocturnal activity relative to the control
mean nocturnal activity (day -1), with a negative value repre-
senting a loss of spontaneous mobility. For each treatment
group, data were further expressed as the area under the
curve over the time course of the primary phase (days 0 to 3)
and the secondary phase (days 4 to 17) of arthritis.
Assessment of proteoglycan metabolism in patellar 
cartilage
Proteoglycan synthesis
Proteoglycan synthesis was studied by an ex vivo incorpora-
tion of Na235SO4 into patellar cartilage. At necropsy, patellas
were collected aseptically, dissected from periarticular tis-
sues, then pulsed for 3 hours at 37°C in a 5% CO2 atmos-
phere with 0.6 μCi/ml Na235SO4 (Amersham, Les Ulis, France)
in RPMI-Hepes 1640 medium supplemented with 2 mM L-
glutamine,100 IU/ml penicillin and 100 μg/ml streptomycin
(Life Technologies, Cergy-Pontoise, France). After five wash-
ings in saline, patellas were fixed overnight in 0.5% cetylpyrid-
inium chloride (Sigma, Saint Quentin-Fallavier, France) in 10%
(v/v) phosphate-buffered formalin, then decalcified in 5% (v/v)
formic acid for 6 hours at room temperature. Biopsy punches,
2 mm in diameter, were taken from the central part of the patel-
las before dissolution overnight in Soluene 350 (Packard,
Rungis, France). 35S-proteoglycan content was measured by
liquid scintillation counting (Hionic Fluor; Packard, Rungis,
France) and data are expressed as the percentage variation
from healthy controls, with a negative value representing a
decrease in proteoglycan synthesis.
Glycosaminoglycans content
Sulphated glycosaminoglycan content was evaluated in patel-
lar cartilage with the 1,9-dimethylmethylene blue (Sigma-
Aldrich, Saint Quentin-Fallavier, France) colorimetric assay
[34]. In brief, patellas were decalcified overnight in 5% (v/v)
formic acid at room temperature before separation of cartilage
layer from underlying bone. Cartilage was dried for 1 day at
room temperature, weighed on a high-precision balance (±
0.01 mg), then hydrolysed for 4 hours at 60°C with 60 μg (0.6
IU) of papain (Sigma, Saint Quentin-Fallavier, France) in enzy-
matic buffer (2 mM dithiothreitol, 1 mM EDTA, 20 mM
Na2HPO4). Hydrolysis was stopped by the addition of iodoac-
etate sodium salt (10 mM final concentration) before neutrali-
zation with Tris-HCl buffer pH 8.0. The assay was performed
by monitoring the metachromatic reaction of sulphated gly-
cosaminoglycans with 1,9-dimethylmethylene blue at 525 nm,
with chondroitin 6-sulphate (Institut Jacques Boy, Reims,
France) as a standard. The calibration curve ranged from 0 to
100 μg/ml chondroitin 6-sulphate, and data are expressed as
μg of glycosaminoglycan per mg of cartilage.Page 3 of 16
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Ankle and knee joints were collected at necropsy, fixed imme-
diately for 24 hours in 4% paraformaldehyde, then decalcified
in rapid bone decalcifier (RDO; Apex Engineering, Plainfield,
IL, USA) for 6 hours at room temperature, and further fixed in
4% paraformaldehyde before embedding in paraffin. Sections
(5 μm thick) were rehydrated in a graded ethanol series and
stained with haematoxylin/eosin/safran and toluidine blue
(ankle joint) or May Grunwald Giemsa (knee joint).
The histological characteristics of ankle articular cartilage,
bone and periarticular soft tissue were scored by a blinded
observer. Cartilage degradation was graded from 0 to 3,
where 0 = fully stained cartilage, 1 = destained cartilage, 2 =
destained cartilage with synovial cells invasion, and 3 = com-
plete loss of cartilage [35]. The following morphological crite-
ria were used for bone erosion: 0 = normal, 1 = mild loss of
cortical bone at few sites, 2 = moderate loss of cortical and
trabecular bone, and 3 = marked loss of bone at many sites
[36].
Synovium from ankle joint was graded using a scoring tech-
nique adapted from Rooney and colleagues [37]. In brief, sam-
ples were evaluated on a scale of 0 to 4 (from 0 = normal to 4
= major changes) for hyperplasia of synovial fibroblasts (depth
of lining layer), fibrosis (percentage replacement of loose con-
nective tissue), focal aggregates of lymphocytes (percentage
aggregate around the lining layer), angiogenesis (number of
proliferating blood vessels), perivascular infiltrates of lym-
phocytes (percentage of vessels surrounded by lymphocytes)
and tissue infiltration by lymphocytes (size of aggregates, per-
centage infiltrating cells). For each group, four or five sections
were taken and graded at different fields to provide a repre-
sentative sample of the whole joint. Mean scores were deter-
mined from the different sections of the individual animals,
allowing the calculation of composite scores for the different
experimental groups.
Analysis of gene expression
RNA isolation
Tibial plateaux, articular fat pad, liver, and peritoneal adipose
tissue were collected aseptically at necropsy and processed
for RNA isolation. Tibial plateaux were decalcified for 12 hours
with 165 mM EDTA pH 7.4 in RNA Later™ (Ambion, Hunting-
don, UK) before separation of the cartilage layer from the
underlying bone. Total RNA was extracted from decalcified
cartilage and frozen tissues by grinding in Trizol™ solution
(Sigma, St Quentin-Fallavier, France). The integrity of the RNA
pool was verified by electrophoresis in agarose gel containing
0.5 μg/ml ethidium bromide.
Gene amplification by PCR
Total RNA (2 μg) was reverse transcribed for 1 hour at 37°C
with 200 U of Moloney murine leukaemia virus reverse tran-
scriptase (Gibco BRL, Cergy-Pontoise, France) using random
hexamer primers (100 pmol) (MWG biotech SA, Courtaboeuf,
France).
In fat pad, PCR amplification was performed on an aliquot of
RT products diluted 10× by Taq polymerase (2.5 U; Gibco
BRL, Cergy Pontoise, France) and specific primers (MWG
biotech SA, Courtaboeuf, France) (Table 1). The conditions
for amplification were: denaturation at 94°C for 45 s, hybridi-
Table 1
Primers used for semi-quantitative PCR and product length
Gene encoding Primer sequence Size (base pairs) Cycles Tm (°C)
L27 Sense: 5'-TCCTGGCTGGACGCTACTC-3' 225 27 62
Antisense: 5'-CCACAGAGTACCTTGTGGGC-3'
MCP-1 Sense: 5'-ATGCAGTTAATGCCCCACTC-3' 167 29 57
Antisense: 5'-TTCCTTATTGGGGTCAGCAC-3'
bFGF Sense: 5'-GAACCGGTACCTGGCTATGA-3' 182 31 61
Antisense: 5'-CCGTTTTGGATCCGAGTTTA-3'
VEGF Sense: 5'-CAATGATGAAGCCCTGGAGT-3' 211 32 64
Antisense: 5'-TTTCTTGCGCTTTCGTTTTT-3'
TNF-α Sense: 5'-AGATGTGGAACTGGCAGAGG-3' 178 31 58
Antisense: 5'-CCCATTTGGGAACTTCTCCT-3'
IL-1β Sense: 5'-TGAAAGCTCTCCACCTCAATGG-3' 366 28 61
Antisense: 5'-TCCATGGTGAAGTCAACTATGTCC-3'
MCP-1, monocyte chemotactic protein-1; bFGF, basic fibroblast growth factor; VEGF, vascular endothelial growth factor; Tm, melting 
temperature.Page 4 of 16
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gation at 72°C for 45 s. The numbers of amplification cycles
were chosen in the exponential phase of PCR. PCR products
were analysed by electrophoresis in 2% agarose gel contain-
ing 0.5 μg/ml ethidium bromide, and quantification was per-
formed with Geldoc 2000™ software (Bio-Rad, Marnes-la-
Coquette, France). The housekeeping gene encoding the
ribosomal protein L27 was used as an internal control, and
results were expressed as the normalized ratio of mRNA level
of each gene of interest over the gene encoding L27.
In other tissues, real-time polymerase chain reaction analysis
was performed with LightCycler™ technology (Roche Diag-
nostics, Basel, Switzerland) and SYBRgreen master mix sys-
tem™ (Qiagen, Courtaboeuf, France). After amplification with
specific primers (Table 2), a melting curve was performed to
determine the melting temperature of each PCR product.
Product sizes were controlled on a 2% agarose gel stained
with 0.5 μg/ml ethidium bromide. Each run included standard
dilutions and positive and negative reaction controls. mRNA
levels of each gene of interest and of the ribosomal protein
RP29, chosen as a housekeeping gene, were determined for
each sample. Results were expressed as the normalized ratio
of the mRNA level of each gene of interest over the gene
encoding RP29.
Bone mineral density
Bone mineral density was determined in vivo by dual-energy
X-ray absorptiometry (DEXA) with a model QDR-4500A den-
sitometer (Hologic Inc., Waltham, MA, USA) and a small-ani-
mal module. Rats were anaesthetized as mentioned above,
placed in a supine decubitus position with abduction of the
four limbs, and scanned both on the day before arthritis induc-
tion (day -1) and on the day before necropsy (day 20). Each
animal was scanned five times consecutively after reposition-
ing, bone mineral density measurement being expressed as
mean ± SD for a single time point. Bone mineral density (g/
cm2) and bone mineral content (BMC, in grams) were deter-
mined on the whole body (total BMC), each measurement
being performed by the same investigator, who was blind to
the treatment. Data were expressed as changes in BMC and
percentage of fat mass over the study duration, each animal
being used as its own control. Internal variations of repeated
measures of total rat bone mineral density have been deter-
mined to be between 1.5% and 2.0%.
Biochemical markers of bone turnover
Plasma osteocalcin level
Heparinized plasma samples were collected on the day before
sensitization (day -1) and at necropsy (day 21) by sampling
veins of the tail and by cardiac puncture, respectively. Plasma
osteocalcin concentration was measured with a sandwich
enzyme-linked immunosorbent assay kit (Biomedical Technol-
ogies Inc., Stoughton, MA, USA). This assay is specific for rat
osteocalcin, with a sensitivity of 0.5 ng/ml. Frozen heparinized
samples were thawed once and diluted 1:10 to 1:20 with sam-
ple buffer in accordance with the manufacturer's recommen-
dations. Data are expressed as changes in plasma osteocalcin
concentration (ng/ml) over the study duration (day 21 minus
day -1), each animal being used as its own control.
Deoxypyridinoline urinary level
Urinary deoxypyridinoline concentration was measured on the
day before arthritis induction (day -1 to day 0) and the day
before necropsy (day 20 to day 21), with a competitive enzyme
immunoassay kit (Metra Biosystems, Palo Alto, CA, USA). This
Table 2
Primers used for real-time PCR and product length
Gene encoding Primer sequence Size (base pairs) Tm (°C)
RP29 Sense: 5'-AAGATGGGTCACCAGCAGCTCTACTG-3' 67 59
Antisense: 5'-AGACGCGGCAAGAGCGAGAA-3'
Aggrecan Sense: 5'-ACACCCCTACCCTTGCTTCT-3' 124 58
Antisense: 5'-AAAGTGTCCAAGGCATCCAC-3'
PPAR-α Sense: 5'-GATGACCTGGAAAGTCCCTT-3' 59 56
Antisense: 5'-CTTGAATGTTTCCCATCTCTT-3'
PPAR-γ Sense: 5'-ATGGGTGAAACTCTGGGAGAT-3' 92 56
Antisense: 5'-GGTAATTTCTTGTGAAGTGCT-3'
Adiponectin Sense: 5'-AATCCTGCCCAGTCATGAAG-3' 433 58
Antisense: 5'-TCTCCAGGAGTGCCATCTCT-3'
ACO Sense: 5'-CCAATCACGCAATAGTTCTGG-3' 362 57
Antisense: 5'-CGCTGTATCGTATGGCGAT-3'
PPAR, peroxisome proliferator-activated receptor; ACO, acyl-CoenzymeA oxidase; Tm, melting temperature.Page 5 of 16
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1.1 nmol/l; it shows acceptable cross-reactivity between ani-
mal species [38]. Spontaneous urine samples were collected
over 24 hours without preservative by placing animals in met-
abolic cages. Frozen urine samples were thawed once and
diluted 1:200 with assay buffer to measure against the stand-
ard curve. Urinary creatinine concentrations (mmol/l) were
determined in parallel with a colorimetric assay kit (Metra Bio-
systems, Palo Alto, CA, USA) and served to correct deoxypy-
ridinoline values for variation in urine concentration. Data are
expressed as changes in deoxypyridinoline/creatinine concen-
tration (nmol/mmol) over the study duration (day 21 minus day
0), each animal being used as its own control.
Statistical analysis
Data are expressed as means ± SEM. Arthritis score and his-
tological grading were analysed with the Mann–Whitney U
test, using StatView™ version 5.0 software (SAS Institute Inc.,
Cary, NC, USA). All other data were compared by analysis of
variance (ANOVA) followed by Fisher's protected least-
squares difference (PLSD) post-hoc test. Differences were
considered significant at P < 0.05 (*, P < 0.05 compared with
normal controls;#, P < 0.05 compared with AIA controls).
Results
Dose–response study with glitazones
Effect of rosiglitazone and pioglitazone on arthritis incidence
As shown in Table 3, arthritis occurred in all animals sensitized
with complete Freund's adjuvant. Treatment with a range of
doses of rosiglitazone or pioglitazone did not reduce arthritis
incidence in three separate experiments, suggesting that
PPAR-γ agonists did not impair the immunological spreading
of the disease.
Effect of rosiglitazone and pioglitazone on gain in body 
weight
In our experimental conditions, the body weight of naive ani-
mals increased gradually, with a mean gain of about 4 to 5 g/
day over the study duration (Figure 1). In all arthritic rats, body
weight peaked at day 10, then decreased progressively as
arthritis settled. The rate of change in body weight was similar
in arthritic controls and in rats treated with 3 mg/kg/day of ros-
iglitazone, or 3 or 10 mg/kg/day of pioglitazone. The decrease
in body weight gain was significantly lower from day 13 to day
20 in arthritic animals receiving 10 mg/kg/day of rosiglitazone
or 30 mg/kg/day of pioglitazone. However, before the onset of
arthritis, rats treated with 30 mg/kg/day of pioglitazone had a
higher weight gain than normal controls. These data demon-
strate that the highest doses of PPAR-γ agonists prevented
arthritis-induced body weight loss, although being able to
favour overweight independently of the arthritic process.
Effect of rosiglitazone and pioglitazone on the course of 
experimental arthritis
The monitoring by biotelemetry showed that arthritic animals
had a biphasic response in their body temperature. An early
peak of fever appeared on day 1, secondary to the local acute
inflammation induced by sensitization, followed by a return to
the control level within 3 days (Figure 2a). A delayed peak of
fever occurred from day 9, when the systemic phase of the
Table 3
Effect of PPAR-γ agonists on incidence of adjuvant arthritis
Group Experiment
1 2 3
AIA 5/5 6/6 7/7
AIA + ROSI 3 5/6 - -
AIA + ROSI 10 5/5 7/7 8/8
AIA + PIO 3 6/6 - -
AIA + PIO 10 6/6 - -
AIA + PIO 30 6/6 6/7 8/8
PPAR, peroxisome proliferator-activated receptor; AIA, adjuvant-
induced arthritis; ROSI, rosiglitazone 3 or 10 mg/kg/day; PIO, 
pioglitazone 3 or 10 or 30 mg/kg/day. Results are disease 
incidences at day 21.
Figure 1
Modulation of body weight gain by rosiglitazone and pioglitazone in the course of adjuvant-induced arthritis
course of adjuvant-induced arthritis. Male Lewis rats were sensitized 
subcutaneously on the basis of the tail with a single injection of 1 mg of 
M. tuberculosis. Animals were treated daily with 3 mg/kg (n = 6) or 10 
mg/kg (n = 12) of rosiglitazone (ROSI) or 3 mg/kg (n = 6), 10 mg/kg (n 
= 6) or 30 mg/kg (n = 12) of pioglitazone (PIO) by oral administration. 
Arthritic (adjuvant-induced arthritis (AIA)) (n = 11) and normal controls 
(n = 10) were given 0.5% carboxymethylcellulose alone. Data are 
expressed as means ± SEM. *, P < 0.05 compared with normal con-
trols; #, P < 0.05 compared with AIA controls (ANOVA and Fisher's 
PLSD post-hoc test). Dn, day n.Page 6 of 16
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mary peak (Figure 2a). Body temperature returned to normal
levels within 5 days and remained stable until the end of the
experiment. Arthritis-induced fever peaks were reduced varia-
bly by PPAR-γ agonists. Rosiglitazone had a moderate inhibi-
tory effect on early fever at 3 mg/kg/day (Figure 2a,b), whereas
it reduced both fever peaks at 10 mg/kg/day (Figure 2a,b,c).
Pioglitazone was ineffective at 3 or 10 mg/kg/day (Figure
2a,b,c). However, it reduced early fever and, more importantly,
delayed fever peak at 30 mg/kg/day (Figure 2a,b,c).
The monitoring of spontaneous locomotive activity showed
that arthritic animals exhibited two successive losses of mobil-
ity (Figure 2d). The first period of hypomobility appeared from
day 1 (-60%) after sensitization, with a partial recovery until
day 4 (-30%). This time course was consistent with the early
peak of fever and probably originated from the acute inflamma-
tion induced by sensitization. A secondary loss of mobility
occurred from day 5 and worsened progressively until day 17
(Figure 2d). Contrary to the delayed peak of fever, secondary
hypomobility was not transient and resulted in a major func-
tional disability (-80% at day 17). Both rosiglitazone and
Figure 2
Modulation of body temperature and locomotive activity by rosiglitazone and pioglitazone treatment during adjuvant-induced arthritis. Animals were 
treated daily with 3 or 10 mg/kg of rosiglitazone (ROSI) or 3, 10 or 30 mg/kg of pioglitazone (PIO) by oral administration. Effect on (a) mean noctur-
nal body temperature, (b) primary inflammation, expressed as area under the time curve (AUC) of body temperature from day 0 to day 3 after sensi-
tization, (c) secondary immunological inflammation, expressed as area under the time curve (AUC) of body temperature from day 4 to day 17 after 
sensitization, and (d) mean locomotive activity. Data are expressed as means ± SEM for at least five animals (ROSI 3, PIO 3 and 10) or 10 animals 
(normal controls, adjuvant-induced arthritis (AIA) controls, ROSI 10 and PIO 30). *, P < 0.05 compared with normal controls; #, P < 0.05 compared 
with AIA controls (ANOVA and Fisher's PLSD post-hoc test). Dn, day n; Nn, night n.Page 7 of 16
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loss of mobility whatever the dosage used.
Anti-arthritic potency of glitazones
Clinical parameters
As shown in Figure 3, arthritis became obvious 11 days after
sensitization and was maximal by day 18. Arthritis was severe:
the mean arthritic score averaged 13 in untreated controls,
highlighting the fact that animals had at least three arthritic
paws (Figure 3a). Arthritis severity was reduced from day 14
by both PPAR-γ agonists, reaching an improvement of 23% for
10 mg/kg/day of rosiglitazone and 49% for 30 mg/kg/day of
pioglitazone on day 21 (Figure 3a). Although paw volume
increased progressively with the age of animals, bilateral hind-
paw swelling was observed from day 14 in arthritic rats (Figure
3b). Contrary to the arthritic score, rosiglitazone was
marginally effective at 10 mg/kg/day (-14% on day 21),
whereas 30 mg/kg/day of pioglitazone reduced oedema by -
54% on day 21 (Figure 3b).
Synovitis
Histological examination of knee joints: overall histological
examination of knee sections from arthritic controls showed a
significant pannus invasion, along with infiltration by mononu-
clear cells and fibrosis, and a slight formation of new blood
vessels (Figure 4a). Cellular infiltration was markedly
decreased in rats treated with one or other glitazone, and no
pannus formation was observed in these conditions (Figure
4a).
Expression of pro-inflammatory genes in fat pad: RT-PCR anal-
ysis showed overexpression of the pro-inflammatory cytokines
TNF-α and IL-1β, of the angiogenic factor vascular endothelial
growth factor (VEGF), of the growth factor bFGF and the
chemokine monocyte chemotactic protein-1 (MCP-1) in fat
pads of arthritic controls (Table 4). Expression of these medi-
ators was not significantly affected in animals receiving 10 mg/
kg/day of rosiglitazone, whereas mRNA levels of IL-1β, TNF-α
and bFGF were decreased by 63%, 77% and 63%, respec-
tively, in rats treated with 30 mg/kg/day of pioglitazone (Table
4). VEGF and MCP-1 mRNA levels were not significantly
affected in these animals.
Histological grading of ankle joints: histological examination of
ankle sections from arthritic controls showed a massive hyper-
plasia of synovial fibroblasts, with focal aggregates of lym-
phocytes and fibrosis (Table 5). A significant proliferation of
blood vessels occurred in the inflamed synovial tissue, with a
moderate perivascular and a marked diffuse infiltration by lym-
phocytes. Lesions were more severe than in corresponding
knee joints, which is consistent with the distal spreading of the
disease. Treatment with 10 mg/kg/day of rosiglitazone or 30
mg/kg/day of pioglitazone decreased synoviocyte hyperplasia,
fibrosis, focal aggregates and diffuse infiltrates of lym-
phocytes, without modifying vessel-related events (angiogen-
esis and perivascular infiltration; Table 5).
Impact of glitazones on cartilage
As shown in Figure 4b, the content of glycosaminoglycans, an
indicator of turnover of proteoglycans, was decreased by 17%
in arthritic controls compared with naive animals. This loss of
glycosaminoglycans was not prevented in rats treated with gli-
tazones. As shown in Figure 4c, radiolabelled sulphate incor-
poration, an indicator of new proteoglycan synthesis, was
markedly decreased in the central and peripheral areas of the
patella in arthritic controls. Once again, arthritis-induced inhi-
bition of proteoglycan synthesis was not significantly reduced
in rats treated with 10 mg/kg/day of rosiglitazone or 30 mg/kg/
day of pioglitazone. RT-PCR analysis showed that aggrecan
expression was also downregulated in tibial plateaux of
Figure 3
Modulation of disease severity by rosiglitazone and pioglitazone treat-ment during adjuvant-induced arthritis
ment during adjuvant-induced arthritis. Animals were treated daily with 
rosiglitazone (ROSI) 10 mg/kg (n = 8) or pioglitazone (PIO) 30 mg/kg 
(n = 8) by oral administration. Arthritic (adjuvant-induced arthritis (AIA)) 
(n = 7) and normal controls (n = 7) were given 0.5% carboxymethylcel-
lulose alone. Arthritis score (a) and paw oedema (b) were assessed 
three times a week after onset of arthritis. For paw volume, each data 
point represents the mean of both hind paws. Data are expressed as 
means ± SEM. *, P < 0.05 compared with normal controls; #, P < 0.05 
compared with AIA controls (Mann–Whitney U test (arthritis score) or 
ANOVA and Fisher's PLSD post-hoc test (oedema)). Dn, day n.Page 8 of 16
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Effect of rosiglitazone and pioglitazone treatment on cartilage changes in arthritic knees. Animals were treated daily for 21 days with rosiglitazone 
(ROSI) 10 mg/kg (n = 8) or pioglitazone (PIO) 30 mg/kg (n = 8) by oral administration. Control animals with adjuvant-induced arthritis (AIA) (n = 7) 
and normal controls (n = 7) were given 0.5% carboxymethylcellulose alone. (a) A representative frontal section of the knee joint showing synovial 
membrane hyperplasia (MGG [May Grunwald Giemsa] staining, day 21 after sensitization). (b, c) Changes in proteoglycan metabolism in patellar 
cartilage: (b) sulphated glycosaminoglycan content by the 1,9-dimethylmethylene blue method expressed as μg of glycosaminoglycan per mg of car-
tilage. Data are expressed as means ± SEM; (c) radiolabelled sulphate incorporation expressed as mean percentage of normal controls. (d) Expres-
sion of aggrecan mRNA level normalized to RP29 in cartilage from tibial plateaux (RT-quantitative polymerase chain reaction). Data are expressed as 
means ± SEM of 4 animals per group. *, P < 0.05 compared with normal controls (ANOVA and Fisher's PLSD post-hoc test).Page 9 of 16
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observed in rats treated with glitazones (Figure 4d). Finally,
histological examination of ankle joints from arthritic controls
revealed limited cartilage degradation, characterized mainly by
a loss of proteoglycan staining. In contrast, AIA controls exhib-
ited severe bone changes, with erosions at the synovium mar-
gin and bone loss (Figure 5). Cartilage lesions were not
decreased in rats receiving glitazones, although a trend was
observed for pioglitazone at 30 mg/kg/day. In contrast, both
rosiglitazone and pioglitazone prevented bone erosion (Figure
5).
Effect of glitazones on bone metabolism
Bone mineral content and fat mass percentage
Changes in BMC and fat mass were evaluated by DEXA on
the whole body. As shown in Figure 6, animals had a similar
BMC and fat mass ratio before sensitization (day 0). In normal
controls, BMC and fat mass ratio increased notably over the
study duration, whereas a limited increase in BMC (Figure 6a)
and a stagnation of fat mass (Figure 6b) were observed in
arthritic AIA controls. The loss of BMC was partly prevented in
arthritic animals treated with 10 mg/kg/day of rosiglitazone or
30 mg/kg/day of pioglitazone (Figure 6a). The percentage of
fat mass returned towards normal values in arthritic rats receiv-
ing 10 mg/kg/day of rosiglitazone but increased over normal
controls in rats treated with 30 mg/kg/day of pioglitazone (Fig-
ure 6b). These data were consistent with the increase in body
weight of pioglitazone-treated rats before arthritis onset (Fig-
ure 1) and suggested that the gain in body weight reflected
both the reduction of inflammation and the growth of adipose
tissue.
Biochemical markers of bone turnover
As shown in Table 6, osteocalcin level decreased with time in
all groups of animals. The changes over the study duration
were not significantly different between the arthritic rats (AIA
controls) and the normal rats, and were modified by neither 10
mg/kg/day of rosiglitazone nor 30 mg/kg/day of pioglitazone
(Table 6). In contrast, the deoxypyridinoline/creatinine urinary
level remained stable in normal controls but increased signifi-
cantly in AIA controls. Treatment with 10 mg/kg/day of rosigl-
itazone or 30 mg/kg/day of pioglitazone tended to decrease
deoxypyridinoline/creatinine levels, although this did not reach
a statistical level of significance (Table 6).
Activation of PPAR-γ target genes by thiazolidinediones
Figure 7 shows that mRNA levels of PPAR-γ and of adiponec-
tin, a PPAR-γ target gene, were similar in peritoneal adipose
tissue of normal or arthritic controls. Expression of both genes
was increased in arthritic rats treated with 10 mg/kg/day of
Table 4
Effect of PPAR-γ agonists on inflammatory genes levels in the knee synovium of arthritic rats
Groups IL-1 TNF-α VEGF bFGF MCP-1
Normal controls 0.23 ± 0.20 0.13 ± 0.07 1.39 ± 0.01 0.41 ± 0.18 0.26 ± 0.14
AIA controls 1.40 ± 0.29* 1.19 ± 0.19* 3.40 ± 1.05* 5.24 ± 0.35* 1.05 ± 0.18*
AIA + ROSI 10 0.98 ± 0.06 1.39 ± 0.16 3.79 ± 0.28 4.59 ± 0.77 1.51 ± 0.22
AIA + PIO 30 0.66 ± 0.16# 0.37 ± 0.11# 4.67 ± 0.21 2.18 ± 0.61# 1.51 ± 0.21
PPAR, peroxisome proliferator-activated receptor; AIA, adjuvant-induced arthritis; ROSI 10, rosiglitazone 10 mg/kg/day; PIO 30, pioglitazone 30 
mg/kg/day; VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; MCP-1, monocyte chemotactic protein-1. Data are 
expressed as means ± SEM of mRNAs of the gene of interest over L27 mRNA (n = 3 representative samples per group).
*, P < 0.05 compared with normal controls; #, P < 0.05 compared with AIA controls (ANOVA and Fisher's PLSD test).
Table 5
Effect of PPAR-γ agonists on the histological grading of ankle synovium in arthritic rats.
Parameter Normal controls AIA controls AIA + ROSI 10 AIA + PIO 30
Synoviocyte hyperplasia 0 ± 0 3.93 ± 0.12* 2.00 ± 0.42# 0.80 ± 0.19#
Focal aggregates of lymphocytes 0.08 ± 0.14 3.50 ± 0.24* 1.60 ± 0.23# 1.20 ± 0.19#
Fibrosis 0.37 ± 0.26 3.73 ± 0.20* 2.60 ± 0.31# 1.00 ± 0.30#
Proliferating blood vessels (original magnification × 40) 0.37 ± 0.26 1.50 ± 0.24* 0.80 ± 0.35 1.07 ± 0.12
Perivascular infiltrates of lymphocytes 0.62 ± 0.26 1.60 ± 0.31* 0.80 ± 0.35 1.10 ± 0.25
Diffuse infiltrates of lymphocytes 0 ± 0 3.13 ± 0.16* 2.10 ± 0.25# 0.70 ± 0.22#
PPAR, peroxisome proliferator-activated receptor; ROSI 10, rosiglitazone 10 mg/kg/day; PIO 30, pioglitazone 30 mg/kg/day; AIA, adjuvant-
induced arthritis. Data are expressed as means ± SEM (n = 5 representative animals per group).
*, P < 0.05 compared with normal controls; #, P < 0.05 compared with AIA controls (Mann–Whitney U test).Page 10 of 16
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mRNA levels of PPAR-α and of acyl-Coenzyme A oxidase, a
PPAR-α target gene, were similar in normal and arthritic con-
trols as well as in rats treated with 10 mg/kg/day of rosiglita-
zone (data not shown). In rats treated with 30 mg/kg/day of
pioglitazone, there was a discrepancy in the induction of these
genes, suggesting that the molecule could be less selective
for PPAR-γ at its effective anti-arthritic dose (data not shown).
These data were consistent with glitazones' being able to
induce PPAR-γ-dependent effects in arthritic rats.
Discussion
In the present study, neither rosiglitazone nor pioglitazone
delayed the onset or reduced the incidence of arthritis, sug-
gesting that the immunological spread of the disease was not
impaired by the dose regimen used. A previous report showed
that PPAR-γ agonists remained anti-arthritic when given after
the early sensitization phase of adjuvant arthritis [21], although
a decreased immunological response contributed partly to the
efficacy of THR0921, a novel PPAR-γ agonist, in mice devel-
oping collagen-induced arthritis [39]. The dose-ranging study
of TZDs was performed by biotelemetry, which provides a
unique opportunity to measure body temperature and
locomotive activity continuously in freely moving conscious
rodents over the study duration [33]. To some degree, telem-
etry reproduces the clinical evaluation of RA because
locomotive activity contributes to algofunctional indices,
whereas fever is not unusual during acute flares [40]. The
arthritic animals displayed a biphasic febrile response that was
previously shown to reflect inflammation linked to sensitization
and immune arthritis, respectively, and to follow the systemic
release of pro-inflammatory cytokines [32]. In our experimental
model, rosiglitazone and pioglitazone decreased both fever
peaks at the highest doses tested but they remained ineffec-
tive towards loss of mobility, which is a pain-dependent event
[32]. Although TZDs are multistep inhibitors of the inducible
arachidonic acid cascade [41], these data do not support a
major contribution of prostaglandin E2, since cyclo-oxygenase
inhibitors were shown to improve the hypomobility of arthritic
animals [33].
These anti-inflammatory properties of TZDs may be due to a
decreased production of pro-inflammatory cytokines such as
TNF-α, IL-1β and IL-6, which have a key role in fever [42] and
Figure 5
Effect of rosiglitazone and pioglitazone treatment on histological grad-ing of ankle lesions duri g adjuvant-i duced arthritis
ing of ankle lesions during adjuvant-induced arthritis. Animals were 
treated daily for 21 days with rosiglitazone (ROSI) 10 mg/kg (n = 8) or 
pioglitazone (PIO) 30 mg/kg (n = 8) by oral administration. Arthritic 
(adjuvant-induced arthritis (AIA)) (n = 7) and normal controls (n = 7) 
were given 0.5% carboxymethylcellulose alone. Cartilage degradation 
and bone erosion were graded as indicated in the Materials and meth-
ods section. Data are expressed as means ± SEM for five representa-
tive animals per group. *, P < 0.05 compared with normal controls; #, P 
< 0.05 compared with AIA controls (Mann–Whitney U test).
Figure 6
Effect of rosiglitazone and pioglitazone treatment on dual-energy X-ray absorptiometry cha ges ur n  adjuvan -induced arthritis
absorptiometry changes during adjuvant-induced arthritis. Animals 
were treated daily for 21 days with rosiglitazone (ROSI) 10 mg/kg (n = 
8) or pioglitazone (PIO) 30 mg/kg (n = 8) by oral administration. 
Arthritic (adjuvant-induced arthritis (AIA)) (n = 7) and normal controls (n 
= 7) were given 0.5% carboxymethylcellulose alone. Dual-energy X-ray 
absorptiometry analysis was performed in vivo the day before arthritis 
induction (day 0) and before necropsy (day 21). (a) Changes in whole-
body bone mineral content (BMC); (b) changes in fat mass percent-
age. Data are expressed as means ± SEM. *, P < 0.05 compared with 
normal controls; #, P < 0.05 compared with AIA controls (ANOVA and 
Fisher's PLSD post-hoc test). Dn, day n.Page 11 of 16
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arthritic mice treated with rosiglitazone [23]. In support of this
proposal, we demonstrated that the highest doses of TZDs
decreased the expression of IL-1β and TNF-α in inflamed syn-
ovium, which is a primary source for systemic inflammatory
cytokines [3]. The major finding of this dose-ranging study was
therefore to indicate that the doses of TZDs required to
decrease inflammation were equal to or greater than those suf-
ficient to restore insulin sensitivity, as reported separately for
troglitazone [25].
The study of the pathophysiological findings of polyarthritis fur-
ther demonstrated that rosiglitazone at 10 mg/kg/day and
pioglitazone at 30 mg/kg/day decreased most aspects of
arthritis severity. These data confirmed that agonists of PPAR-
γ are potential therapeutic agents for arthritis [21,23,25,39],
although they displayed a variable ability to activate this recep-
tor subtype [39,43]. From that point of view, rosiglitazone was
shown to be at least 10-fold more active than pioglitazone in
transactivation assays with murine or human PPAR-γ chimeric
receptors [43]. In addition, pharmacokinetics studies demon-
strated that a single oral dose of 10 mg/kg/day in rats provided
a maximal plasma concentration that was twice as high with
rosiglitazone [44] as with pioglitazone [45]. In addition, the
plasma levels of pioglitazone were shown previously to be
lower in male rats than in female rats for a given dose [45]. As
a consequence, one might expect that the threefold higher
dose of pioglitazone would provide circulating levels in the
same range as rosiglitazone in our arthritic male rats. This
threefold dose ratio between pioglitazone and rosiglitazone
was also consistent with their therapeutic use in patients with
type 2 diabetes, although it cannot be considered a reliable
indicator of their transactivating properties on PPAR-γ. Of par-
ticular note is our result that animals receiving 30 mg/kg/day
of pioglitazone had a significantly higher gain in body weight
before arthritis onset. To our knowledge, this is the first
description of such a side effect in rodents developing arthri-
tis, although it was highly consistent with the weight gain
observed in diabetic patients treated with TZDs [46]. Further-
more, the DEXA analysis revealed a higher than normal per-
centage of fat mass in these animals, which reproduced the
increased fatness seen in the clinics, even if a favourable
redistribution of fat from visceral to subcutaneous depots was
also reported [47]. This drawback was probably attributable to
the ability of PPAR-γ to induce adipocyte differentiation [48],
because we demonstrated that both TZDs stimulated the
expression of adiponectin, a PPAR-γ-sensitive gene [49], in
the adipose tissue of arthritic rats. However, the increased fat-
ness was observed only in the group displaying the less
severe arthritis. This suggests that a lower caloric cost of the
disease could also contribute to the changes in body weight
observed in animals treated with 30 mg/kg/day of pioglitazone
[50].
The reduction of synovitis in animals treated with 10 mg/kg/
day of rosiglitazone or 30 mg/kg/day of pioglitazone extended
the general meaning that inflamed synovium was a target for
the anti-arthritic potency of TZDs [21-23,25,39]. The
decrease in synovial hyperplasia seemed unlikely to have
resulted from an increased apoptosis of synovial fibroblasts
[25], because rosiglitazone had been shown to decrease
apoptotic cells in connected tissues around the joints of
arthritic mice [22]. As mentioned previously, we demonstrated
that both TZDs reduced the expression of IL-1β and TNF-α in
arthritic synovium, a finding consistent with a recent report of
their decrease by the PPAR-γ agonist THR0921 in joints of
mice with established collagen-induced arthritis [39]. This
could be due to the ability of PPAR-γ agonists to inhibit the NF-
Table 6
Effect of PPAR-γ agonists on biochemical markers of bone 
turnover in rats with adjuvant arthritis
Group Change in plasma 
osteocalcina (ng/ml)
Change in urinary 
deoxypyridinolineb (nmol/
mmol creatinine)
Normal controls -39 ± 11 -3 ± 6
AIA controls -50 ± 9 24 ± 7*
AIA + ROSI 10 -37 ± 12 9 ± 4
AIA + PIO 30 -32 ± 16 12 ± 5
PPAR, peroxisome proliferator-activated receptor; AIA, adjuvant-
induced arthritis; ROSI 10, rosiglitazone 10 mg/kg/day; PIO 30, 
pioglitazone 30 mg/kg/day. Data are expressed as means ± SEM (n 
= 5 for deoxypyridinoline; n = 6 for osteocalcin).
*, P < 0.05 compared with normal controls (ANOVA and Fisher's 
PLSD test). aDay 21 minus day -1; bday 21 minus day 0.
Figure 7
Effect of rosiglitazone and pioglitazone treatment on expression of PPAR target genes duri g adjuvant-i duced arthritis
PPAR target genes during adjuvant-induced arthritis. Animals were 
treated daily for 21 days with rosiglitazone (ROSI) 10 mg/kg or pioglita-
zone (PIO) 30 mg/kg by oral administration. Arthritic (adjuvant-induced 
arthritis (AIA)) and normal controls were given 0.5% carboxymethylcel-
lulose alone. mRNA levels of adiponectin and peroxisome proliferator-
activated receptor (PPAR)-γ normalized to RP29 in adipose tissue were 
assessed by RT-quantitative polymerase chain reaction. Data are 
expressed as means ± SEM for three representative samples per group 
(arthritis score close to the mean score of the group). #, P < 0.05 com-
pared with AIA controls (ANOVA and Fisher's PLSD post-hoc test).Page 12 of 16
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between arthritis models might explain why we failed to
observe any significant decrease in the chemokine monocyte
chemoattractant expression in TZDs-treated rats, in contrast
with mice treated with THR0921 [39]. We showed further that
TZDs decreased the expression of bFGF, which is a powerful
mitogen for both synovial fibroblasts and endothelial cells
whose neutralization was reported to attenuate arthritis sever-
ity [51]. Its reduced expression could therefore contribute to
the anti-arthritic potency of these molecules. Finally, we dem-
onstrated that neovascularization and expression of VEGF
were reduced by neither pioglitazone nor rosiglitazone,
despite a marked decrease in synovitis. Angiogenesis has a
pivotal role in RA by increasing the exchange of cells,
cytokines and growth factors from the bloodstream to the joint
cavity, thereby promoting tissue infiltration and pannus growth
[52]. Pro-inflammatory cytokines [53] and bFGF [54] are
strong inducers of VEGF release, and their inhibition by TZDs
may lower neovascularization in the same way as anti-cytokine
therapies in rheumatoid patients [53] or arthritic rats [55]. In
contrast, TZDs were reported to stimulate VEGF expression in
several cell types [56] and to increase its plasma level in type
2 diabetic patients [57], therefore suggesting that they could
counterbalance the impact of their anti-inflammatory effect on
the formation of new vessels.
The decrease in 35S-sulphate incorporation into proteoglycans
[58] and secondary loss of proteoglycan content in cartilagi-
nous tissue [59] are hallmarks of the chronic phase of adjuvant
arthritis. In addition, biochemical changes in patellar cartilage
were shown to be representative of the entire arthritic joint
[60] and to be very sensitive to the inhibitory effect of pro-
inflammatory cytokines [61]. Thus, our data were highly homo-
geneous because the decreased proteoglycan synthesis and
aggrecan expression in cartilage resulted in a significant loss
of proteoglycans and decreased cartilage staining in arthritic
controls. However, the anti-inflammatory effect of TZDs failed
to provide significant protection to cartilage in both the knee
and ankle joints. Our results differ from previous reports of
decreased histological lesions in arthritic joints of rodents
treated with glitazones [23,25], although this difference could
be supported, at least in part, by the scoring system used.
Indeed, cartilage and bone changes were always assessed
concomitantly [23,25], whereas we checked separately for
cartilage [35] and bone [36] changes in our arthritic rats. Had
we considered both changes together, we would have demon-
strated a possibly protective effect of TZDs in arthritic joints
but it would have been supported by an improvement in bone
lesions rather than in cartilage lesions. In addition, we demon-
strated recently that selective agonists of the three PPAR iso-
types decreased the anabolic response of chondrocytes to
TGF-β [62]. Because rat chondrocytes embedded in alginate
beads are close to cartilage samples [63], one cannot exclude
the possibility that the lack of restoration of proteoglycan
metabolism by TZDs could be also supported by a diminished
response of arthritic cartilage to TGF-β.
A major finding of the present work was that rosiglitazone and
pioglitazone prevented arthritis-induced bone loss. PPAR-γ
agonists were shown previously to decrease bone erosion
[23,24] and to improve the radiographic score [24] in arthritic
rodents. The contribution of synovitis to bone loss, ranging
from focal erosions to periarticular or generalized osteopenia,
has become a very active topic in RA [24]. Further confirming
histological findings, the DEXA analysis showed that the pro-
tective effect of TZDs was detectable on the whole body and
in selected regions of interest (data not shown), suggesting
that they were active on cortical and trabecular bone. Bone
loss is a classical feature of adjuvant arthritis, in which an
increase in the number of osteoclasts and in the formation of
osteoclast precursors from the monocyte/macrophage com-
partment in the synovium was reported within few days after
disease onset [64]. Focal bone erosions and generalized bone
loss are thought to be secondary to an overload of pro-inflam-
matory cytokines [6], whose osteoclastogenic effect has
recently been ascribed to RANKL [10]. Thus, administration of
osteoprotegerin, which prevents the binding of RANKL to
RANK, decreased arthritis-induced bone loss [65], suggest-
ing that TZDs may prevent bone loss, at least in part, by
decreasing the production of inflammatory cytokines in
inflamed synovium. In additon, PPAR-γ agonists were shown
to decrease the phosphorylation of the inhibitor IκB in arthritic
joints [22], and inhibition of the NF-κB pathway prevented
inflammatory bone destruction in vivo by blocking osteoclas-
togenesis [66]. Moreover, PPAR-γ agonists were shown to
inhibit RANKL-dependent differentiation of osteoclasts in
bone marrow cells [39,67] or peripheral blood mononuclear
cells [21,68]. A decrease in bone resorption was also sup-
ported by the decreased urinary excretion of deoxypyridinoline
[38] in rats treated with TZDs. The bone-protective potency of
TZDs is very provocative because these molecules were
reported to cause bone loss in rodents [69,70] or type 2
diabetic patients [71,72] by switching the differentiation of
bone precursors towards an adipogenic phenotype [69,70].
Our data therefore suggest that the differentiating effect of
PPAR-γ agonists on adipocytes [48] may have a variable
impact on bone depending on the inflammatory status of the
body.
Conclusion
The present work confirms that an oral intake of the antidiabet-
ics rosiglitazone or pioglitazone can reduce the severity of
arthritis but indicates that the doses required for an anti-
arthritic effect exceed those sufficient to restore insulin sensi-
tization. This effect is due, at least in part, to their ability to
decrease the expression of pro-inflammatory cytokines in
inflamed synovium without affecting neovascularization.
Thiazolidinediones prevent inflammatory bone loss but do not
improve changes in proteoglycans in arthritic cartilage. How-Page 13 of 16
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with increased adiposity in arthritic animals, suggesting that a
strong activation of PPAR-γ may expose arthritic patients to
the drawbacks of excessive adipocyte differentiation.
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